FDA Adds “Consultation Meetings” To Patient-Focused Drug Development Effort
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is seeking patient community input on process issues related to holding 20 meetings on disease-specific areas over the next five years under PDUFA V. FDA has proposed 39 medical conditions that could be considered for those disease-specific meetings.